We serve Chemical Name:1,8-naphthyridine-2,7-diamine CAS:145325-89-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:1,8-naphthyridine-2,7-diamine
CAS.NO:145325-89-9
Synonyms:2,7-diamine-1,8-naphthyridine;2,7-Diamino-1,8-naphthyridine
Molecular Formula:C8H8N4
Molecular Weight:160.17600
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:79.28000
Exact Mass:160.07500
LogP:0.65440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,7-diamine-1,8-naphthyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,7-Diamino-1,8-naphthyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,7-Diamino-1,8-naphthyridine Use and application,2,7-Diamino-1,8-naphthyridine technical grade,usp/ep/jp grade.
Related News: Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. 1,8-naphthyridine-2,7-diamine manufacturer Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 1,8-naphthyridine-2,7-diamine supplier The Environmental Working Group, a nonprofit advocacy organization, applauded the bill’s introduction. 1,8-naphthyridine-2,7-diamine vendor Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. 1,8-naphthyridine-2,7-diamine factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
